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Abstract
Recent studies have implicated the dying cell as a potential 
reservoir of modified autoantigens that might initiate and drive 
systemic autoimmunity in susceptible hosts. A  number of 
subunits of the exosome, a complex of 3 '—>5' exoribonucleases 
that functions in a variety of cellular processes, are recognized 
by the so-called anti-PM/Scl autoantibodies, found 
predominantly in patients suffering from an overlap syndrome of 
myositis and scleroderma. Here we show that one of these 
subunits, PM /Scl-75, is cleaved during apoptosis. PM/Scl-75 
cleavage is inhibited by several different caspase inhibitors. The
analysis of PM /Scl-75 cleavage by recombinant caspase 
proteins shows that PM /Scl-75 is efficiently cleaved by 
caspase-1, to a smaller extent by caspase-8, and relatively 
inefficiently by caspase-3 and caspase-7. Cleavage of the PM/ 
Scl-75 protein occurs in the C-terminal part of the protein at 
Asp369 (IILD369-lG), and at least a fraction of the resulting N- 
terminal fragments of PM /Scl-75 remains associated with the 
exosome. Finally, the implications of PM /Scl-75 cleavage for 
exosome function and the generation of anti-PM/Scl-75 
autoantibodies are discussed.
Introduction
System ic autoimmune diseases are characterized by the pres­
ence of autoantibodies reactive to a w ide variety of autoanti­
gens. W hy these autoantibodies, which escape the normal 
mechanisms ensuring self tolerance, are made is still not fully 
understood. However, the occurrence of modified self-anti­
gens during (either apop to tic  or necrotic) cell death in com bi­
nation w ith a defective clearance of dead cells has been 
proposed to have a role in the development of autoimmunity 
(reviewed in [1,2]). In apop to tic  cells many autoantigenic p ro­
teins or complexes can be m odified by processes such as 
(de)phosphorylation, citrullination, nucleolytic cleavage or p ro­
teolytic cleavage by caspases (reviewed in [3]). The m odifica­
tion and redistribution of these proteins m ight generate 
antigenic determ inants to which no tolerance exists, thereby 
eliciting a primary immune response. Via epitope spreading,
VSV-G =  vesicular stom atitis virus G epitope.
the initial response, directed to the neo-epitope resulting from 
the modification, could evolve to a secondary response in 
which antibodies arise that are reactive w ith other, unmodified 
parts of the protein or w ith proteins that are associated w ith 
the modified antigen [1,4].
Patients suffering from myositis and scleroderm a (Scl), which 
is called the polym yositis/scleroderm a overlap syndrome (PM / 
Scl), produce antibodies against a variety of autoantigens. 
Some of these are also found in patients suffering from myosi­
tis or scleroderm a alone. Autoantibodies recognizing the so- 
called PM /Scl autoantigen are found in 24 to 31%  of all 
patients w ith PM /Scl [5-8], and in only 2 to 6%  of patients suf­
fering from myositis or scleroderma alone [7,9]. O f all patients 
positive fo r anti-PM /Scl antibodies, between 43%  and 88%  
are diagnosed w ith a m yositis/scleroderm a overlap syndrome
Page 1 o f 9
(page num ber no t for c ita tion  purposes)
Arthritis Research & Therapy Vol 9 No 1 Schilders et al.
[7,10]. The PM /Scl autoantigen is the human homologue of 
the yeast exosome, which consists of at least nine core pro­
teins, all displaying exoribonuclease characteristics. The exo- 
some has been shown to be involved in the degradation and 
processing of many different RNA species [11,12]. A lthough 
the nuclear exosome com ponent P M /S cl-100 and the two 
core exosome com ponents P M /S cl-75 and hRrp4p carry the 
main autoantigenic epitopes, autoantibodies d irected against 
PM -Scl-75 seem to be the most prevalent in patients w ith the 
polym yositis/scleroderm a overlap syndrome [8]. The cDNA- 
derived amino acid sequence fo r P M /S cl-75 was published in 
1991 and is now referred to as PM /Scl-75a-a. A  splic ing var­
iant of PM /Scl-75a containing an additional exon in the C -ter­
minal region of the protein is known as PM /Scl-75a-ß [13]. 
More recently, we found that the PM /Scl-75a cDNA sequence 
is probably incomplete, and identified a P M /S cl-75 cDNA 
(referred to as PM /Scl-75c) encoding an additional N-terminal 
part that is required for association w ith the exosome complex 
[14].
Until now, none of the subunits of the exosome complex had 
been shown to be m odified during apoptosis, prom pting us to 
investigate the m olecular characteristics of exosome subunits 
in apop to tic  cells. Here we demonstrate that the PM /Scl-75 
protein is cleaved in a caspase-dependent manner during 
apoptosis and that th is cleavage occurs in the C-terminal 
domain of the protein at residue Asp369.
Materials and methods
Cell lines
Jurkat cells (human T-cell leukemia, A T C C  CR L-2570), Peer 
cells (human T-cell leukemia) and CCRF-CEM  cells (human T- 
cell lym phoblastic leukemia, A T C C  C C L-119) were grown in 
RPM I-1640 medium (G ibco-BRL, Gaithersburg, USA) supple­
mented w ith 10%  heat-inactivated fetal calf serum, 1 mM 
sodium pyruvate, penicillin (100 units/ml), and streptom ycin 
(100 |ig /m l). Jurkat cells stably transfected w ith Bcl-2 (Jurkat/ 
Bcl-2) or w ith the empty transfection vector (Jurkat/Neo) were 
cultured in the same medium w ith the addition of 200 |ig /m l 
G 4 1 8  (G ibco-BRL).
Induction of cell death
To induce apoptosis, Jurkat cells were treated w ith the agonis­
tic  anti-Fas m onoclonal antibody 7 C 1 1 as described previ­
ously [15 ,16]. Peer and CCRF-CEM  cells were treated with 
0.5 |ig /m l actinomycin D, 10 |ig /m l anisomycin, 100 |ig /m l 
cyclohexim ide or 400  nM staurosporin. CCRF-CEM  cells were 
also treated w ith the anti-Fas antibody. The efficiency of apop­
tosis induction was assessed by flow  cytometry w ith the use 
of staining w ith fluorescein isothiocyanate-coupled annexin V 
and propidium  iodide (PI) as described previously [15]. A fte r 
8 hours generally more than 90%  of the cells were apoptotic. 
A fte r harvesting of the dying cells, cells were washed tw ice 
w ith phosphate-buffered saline and used immediately or 
stored at -70°C. For experiments w ith the cell-permeable
tetrapeptide caspase inhibitors (Calbiochem, Darmstadt, G er­
many), Jurkat cells were cultured for 1 hour in the presence of
2 or 20 |iM  Ac-YVAD-CM K, Z-DEVD-FMK, Z-IETD-FMK or Z- 
LEHD-FMK (irreversible inhibitors of caspase-1, caspase-3/-7, 
caspase-8 and caspase-9, respectively) as described previ­
ously [16]. The specific ity of these inhibitors is based on in 
vitro  assays w ith purified caspases. Their specific ity in a cellu­
lar context is d ifficu lt to define. Subsequently, apoptosis was 
induced by the addition of anti-Fas m onoclonal antibody fo l­
lowed by harvesting the cells after 8 hours of incubation.
Western blot analysis
Cells were lysed on ice for 30 minutes in Nonidet P40 lysis 
buffer (25 mM Tris-HCl, pH 7.5, 1% Nonidet P40, 100 mM KCl, 
10 mM M gC l2, 1 mM dithiothreitol), containing a protease inhib­
itor cocktail (Complete; Roche, Mannheim, Germany). Cell 
lysates were centrifuged for 15 minutes at 4°C  (12,000 g) and 
the supernatants were used immediately or stored at -70°C. 
Protein extracts of 106 cells were analyzed by 10%  SDS-PAGE 
and W estern blotting w ith systemic lupus erythematosus 
patient serum Ven96 (a patient serum reactive with many exo- 
some subunits), an anti-PM /Scl-100 rabbit serum [17] or an 
anti-PM /Scl-75 rabbit or mouse serum [18], followed by detec­
tion by means of horseradish peroxidase-conjugated secondary 
antibodies and visualization by chemiluminescence.
Immunoprecipitation
Protein A -agarose  beads (20 |il of 50%  slurry) were coated 
w ith 20 |jJ of Ven96 patient serum, anti-hR rp46p rabbit serum 
[17] or anti-PM /S cl-75 [18] rabbit serum. Incubations were 
performed overnight at 4°C  in IPP500 buffer (500 mM NaCl, 
10 mM Tris-HCl, pH 8.0, 0.1%  Nonidet P40) by end-over-end 
rotation. A fter the beads had been washed three tim es w ith 
IPP150 (com position sim ilar to IPP500, but containing 150 
mM NaCl), the beads were incubated w ith 20 |il (2 x  106 cell 
equivalents) of Jurkat extract (control or apoptotic) in IPP150 
by end-over-end rotation fo r 2 hours at 4°C. A fte r three wash 
steps w ith IPP150, the beads were resuspended in protein 
sample buffer and im m unoprecipitated proteins were analysed 
by SDS-PAG E and W estern blotting.
Plasmids
The cDN As of P M /S cl-75a-a  (GenBank accession number 
M 58 46 0 ) and P M /S cl-75c-a  (accession number A J505989) 
[14] were cloned into the EcoRI and XbaI sites of the pCI-neo 
vector (Promega, Madison, USA), containing an in-frame 
vesicular stom atitis virus G epitope (VSV-G) tag at either the 
5 ' end or the 3' end of the cDNAs. For identification of the cas­
pase cleavage site, mutant cDNAs of PM /Scl-75 were gener­
ated, encoding substitution mutants in which one of the 
aspartic acid residues at positions 272, 304, 307, 349, 352, 
357, 358, 363, 369, 37 4  and 381 were replaced by alanine. 
All mutants were generated by a megaprimed PCR-based 
approach w ith a P M /Scl-75 cDNA as a tem plate and specific  
primers overlapping the regions that were mutated. The result-
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Cleavage of the PM /S cl-75 protein during anti-Fas-induced apoptosis. (a ) Jurkat cells were treated w ith the anti-Fas monoclonal antibody 7C11 for 
the indicated durations. Protein extracts were analyzed by 10%  SDS-PAG E and W estern blotting w ith a polyclonal anti-PM /Scl-75 rabbit serum. (b ) 
Jurkat/Neo and Jurkat/Bcl-2 cells were treated w ith the anti-Fas monoclonal antibody 7C11 for the indicated durations. Protein extracts were ana­
lyzed by 10%  SDS-PAG E and W estern blotting w ith the anti-PM /Scl-75 rabbit serum. In each panel the positions o f molecular mass markers are 
indicated in kDa at the right and the positions o f the relevant po lypeptides are shown at the left. Filled arrowheads indicate full-length proteins, open 
arrowheads indicate cleavage products and the asterisk indicates a cross-reactivity o f the anti-PM /Scl-75 serum w ith an unknown protein.
ing PCR products were purified, and then cloned into the 
pC R4-TO PO  (Invitrogen, Carlsbad, USA) or pCI-neo vector. 
The integrity of the mutant constructs was confirmed by DNA 
sequencing. The resulting cDN As were used as tem plates for 
in vitro transcription/translation of the respective proteins.
In vitro cleavage assay
Proteins were generated by in vitro transcription and transla­
tion w ith the TnT T7-coupled rabbit reticulocyte lysate system 
(Promega) as described by the manufacturer. For detection of 
the translation products, [35S]m ethionine was added to the 
translation reactions. Proteins translated in vitro were incu­
bated w ith the purified murine recombinant caspases at 200 
nM in a total volume of 25 |il of CFS buffer (220 mM mannitol, 
68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO 4, 10 mM 
HEPES, pH 7.4, 1  mM aprotinin, 1  mM leupeptin, 1  mM phe- 
nylmethylsulfonylfluoride, supplem ented w ith 10 mM dithioth- 
reitol) for 1.5 hours at 37°C. The resulting cleavage products 
were analyzed by 10%  SDS-PAG E and W estern blotting fo l­
lowed by autoradiography.
Results
Cleavage of PM/Scl-75 during apoptosis
To study the potential modification of human exosome com po­
nents during apoptosis, Jurkat cells were treated w ith the ago­
nistic anti-Fas antibody 7C11 and cell extracts were analyzed 
by W estern b lotting w ith a patient's serum (Ven96) known to 
be reactive w ith the major autoantigenic exosome com ponents 
P M /Scl-100, PM /Scl-75 and hRrp4p. The results of this anal­
ysis demonstrated that the intensity of the P M /S cl-75 band 
was strongly reduced after the induction of apoptosis, 
whereas the signals of P M /S cl-100 and hRrp4p were only 
slightly dim inished (data not shown). To analyze this phenom ­
enon in more detail, a similar blot was analyzed w ith a rabbit
serum raised against P M /S cl-75 (Figure 1a). The result con­
firmed that most full-length P M /Scl-75 disappeared during 
apoptosis, concom itant w ith the appearance of a faster- 
m igrating polypeptide at approximately 45 kDa (Figure 1a, 
lane 3). To investigate whether the production of this putative 
PM /Scl-75 cleavage fragm ent was indeed dependent on the 
induction of apoptosis, the cleavage of P M /S cl-75 was ana­
lyzed in anti-Fas-stimulated normal Jurkat cells (Jurkat/Neo) 
and Jurkat cells overexpressing Bcl-2 (Jurkat/Bcl-2). In the Jur- 
kat/Bcl-2 cells the induction of apoptosis has been dem on­
strated to be delayed considerably by preventing cytochrome 
c release and caspase activation [15]. Indeed, the PM /Scl-75 
cleavage product was produced in the Jurkat/Neo cells but 
could not be detected in the Jurkat/Bcl-2 cells, not even after 
8 hours of anti-Fas treatment (Figure 1b).
To investigate whether cleavage of P M /S cl-75 also occurred 
in other cells and on exposure to other apop to tic  stimuli, we 
analyzed lysates of other cell lines as well as lysates from lym­
phocytes isolated from peripheral blood in which apoptosis 
had been induced in various ways. CCRF-CEM  cells were 
exposed to actinomycin D, anisomycin, cycloheximide, stau- 
rosporin or anti-Fas antibodies and Peer cells were cultured in 
the presence of actinomycin D, anisomycin, cyclohexim ide or 
staurosporin, and after 8 hours extracts of these cells were 
analyzed by W estern blotting (Figure 2). Except for the CCRF- 
CEM cells treated w ith actinomycin D (lane 2) and with 
cycloheximide (lane 4), a decrease in the full-length PM /Scl-75 
signals and the appearance of the cleavage product of PM / 
S cl-75 was detected in all lysates, indicating that PM /Scl-75 
cleavage is a general phenomenon in apop to tic  cells. As can 
be seen in Figures 1 and 2, the anti-PM /S cl-75 rabbit serum 
also showed reactivity w ith a number of as yet unidentified 
proteins. A pop to tic  modification of PM /Scl-75 was also
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Cleavage of the P M /S c l-75  protein in various cell types treated w ith d if­
ferent apoptosis inducers. CCRF-CEM cells were treated w ith actino­
mycin D (A), anisomycin (AN), cyclohexim ide (C), staurosporin (S) or 
anti-Fas mAb 7C11 (a-Fas); Peer cells were treated w ith actinomycin 
D (A), anisomycin (AN), cycloheximide (C) o r staurosporin (S). Cell 
extracts were analyzed by 10%  SDS-PAG E and W estern blotting w ith 
the anti-PM /Scl-75 rabbit serum. Extracts from mock-treated cells were 
loaded in lanes 1 and 7. The positions o f molecular mass markers are 
indicated in kDa at the right and the positions of the relevant polypep­
tides are shown at the left. Filled arrowheads indicate full-length pro­
teins and open arrowheads indicate cleavage products; the asterisk 
indicates a cross-reactivity w ith an unidentified protein.
PM/Scl-75 cleavage is caspase mediated
Because the activation of caspases is a common feature of 
apop to tic  cells and because activated caspases are capable 
of cleaving a large number of (autoantigenic) proteins, we 
investigated whether caspase activation was required for 
cleavage of PM /Scl-75. Jurkat cells were cultured in the pres­
ence of various inhibitors of caspases for 1 hour before the 
induction of apoptosis by anti-Fas. Four different tetrapeptide 
caspase inhibitors were used, namely Ac-YVAD-C M K for 
group I caspases (caspase-1-like), Z-DEVD-FMK fo r group II 
caspases (caspase-3-like), and Z-IETD-FMK (caspase-8) and 
Z-LEHD-FM K (caspase-9) fo r group III caspases. Rabbit anti- 
P M /S cl-75 antiserum was used to analyze the cleavage of PM/ 
S c l-75 in these cells. The cleavage of P M /S cl-75 was com ­
pletely inhibited in the presence of 2 or 20 |iM  Ac-YVAD-CM K, 
Z-DEVD-FMK or Z-IETD-FMK (Figure 4, lanes 4 to 9). In the 
presence of Z-LEHD-FMK, PM /Scl-75 cleavage was partly 
inhibited at 2 |iM  and com pletely inhibited in the presence of 
a 10-fold higher concentration (Figure 4, lanes 10 and 11). As 
a contro l for the inhibitory activity of the tetrapeptide inhibitors, 
the cell extracts were also analyzed fo r cleavage of U1-70K 
and Sm-F. The inhibition of cleavage of both caspase sub­
strates seemed to be very sim ilar to that observed fo r PM /Scl- 
75 (data not shown). These results suggest that caspases, or 
other proteases activated downstream of the caspase cas­
cade, are involved in the apop to tic  cleavage of PM /Scl-75.
observed in the lysates from the lymphocytes on treatment 
w ith anti-Fas antibodies or ionomycin for 6 hours (data not 
shown).
Association of the PM/Scl-75 cleavage fragment with 
the exosome complex
The most obvious explanation of the results described above 
is that P M /S cl-75 is cleaved by a protease that is activated in 
apop to tic  cells, resulting in two proteolytic fragments. 
Because the rabbit antiserum is reactive only w ith the 45 kDa 
fragment, our data do not exclude the possib ility that the other 
fragm ent is further degraded. P M /S cl-75 is one of the core 
com ponents of the exosome complex, and most PM /Scl-75 
m olecules in a cell are believed to be associated w ith this com ­
plex. To analyze whether the apop to tic  cleavage fragm ent of 
P M /S cl-75 can associate w ith the exosome complex, immuno- 
precip itations were performed w ith extracts from contro l and 
apop to tic  Jurkat cells. The results in Figure 3 show  that not 
only anti-PM /S cl-75 rabbit serum and patient serum Ven96, 
but also rabbit antibodies against hRrp46p, another exosome 
core subunit, (co-)precip itated both the w ild-type and the 
cleaved P M /S cl-75 protein. Note that in this experiment PM/ 
S cl-75 was detected by a polyclonal mouse serum raised 
against the recombinant protein. This result indicates that at 
least a subset of cleaved P M /Scl-75 m olecules either binds to 
the exosome or remains associated w ith the core of the 
exosome.
Cleavage of PM/Scl-75 by different caspases
To determ ine whether P M /S cl-75 is a d irect substrate for cas­
pases, PM /S cl-75 translated in vitro was incubated w ith 
recombinant murine caspase-1, caspase-2, caspase-3, 
caspase-7, caspase-8 and caspase-11. Four of these cas- 
pases seemed to be able to cleave PM /Scl-75, resulting in 
cleavage products sim ilar in size to the fragm ent generated in 
vivo (Figure 5 a). However, the efficiencies by which this p ro­
tein is cleaved by the recombinant caspases showed marked 
differences. Caspase-1 very efficiently cleaved PM /Scl-75, 
whereas decreasing efficiencies were observed for caspase- 
8, caspase-7 and caspase-3. The recombinant caspase-2 and 
caspase-11 did not result in detectable levels of PM /Scl-75 
cleavage (Figure 5 a, lanes 3 and 7). As a contro l fo r caspase 
activity, all recombinant caspases were incubated w ith a spe­
c ific  fluorogenic substrate (Figure 5 b). Because caspase-8 
has a key role in apoptosis mediated by a death domain recep­
tor, we tested whether caspase-8 is essential for the cleavage 
of PM /S cl-75 in apopto tic cells: caspase-8-deficient Jurkat 
cells (ATCC C R L-2571) were used to analyze the apopto tic 
processing of PM /Scl-75. These cells become apopto tic 
when treated w ith staurosporin in combination w ith cyclohex- 
imide. Despite the absence of caspase-8, on induction of 
apoptosis the same cleavage pattern was observed as in con­
trol cells containing caspase-8 (data not shown). This sug­
gests that, in agreement w ith the proteolysis results in vitro, 
other caspases contribute to the cleavage of PM /S cl-75 in 
apop to tic  cells.
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Figure  3
The apopto tic  cleavage product of PM /Scl-75 remains associated w ith the exosome. Im m unoprecip itations from control (0 hours) and apopto tic (8 
hours incubated w ith anti-Fas antibody) Jurkat cell extracts w ere performed w ith normal rabbit serum (lanes 3 and 4), anti-PM /Scl-75 (lanes 5 and 6) 
and anti-hR rp46p (lanes 7 and 8) rabbit sera, and patient serum Ven96 (lanes 9 and 10). In lanes 1 and 2 input samples, 20%  of the total control 
and apopto tic  cell extracts, respectively, were loaded. Im m unoprecipitates were analyzed by 10%  SDS-PAG E and W estern blotting w ith a po lyclo­
nal anti-PM /Scl-75 mouse serum. The positions of the PM /S cl-75 protein (filled arrowhead), its cleavage product (open arrowhead) and a cross­
reactivity of the anti-PM /scl-75 serum (asterisk) are indicated at the left. The positions of molecular mass markers are indicated in kDa at the right.
F ig u re  4
Inhibition o f PM /S cl-75 cleavage by caspase inhibitors. Jurkat cells were cultured for 1 hour at 37 °C  in the presence of four cell-perm eable te trapep­
tide caspase inhibitors: 2 |iM  (lanes 4, 6, 8 and 10) or 20 |iM  (lanes 5, 7, 9 and 11) inhibitors o f caspase-1 (YVAD), caspase-3 (DEVD), caspase-8 
(IETD) and caspase-9 (LEHD). Subsequently, cells were cultured for 8 hours in the presence of anti-Fas monoclonal antibody (a-Fas). Control 
extract from mock-treated Jurkat cells was loaded in lane 1. In lanes 2 and 3 extracts from control and apopto tic  (8 hours anti-Fas mAb) Jurkat cells, 
respectively, were analyzed. Total protein extracts were analyzed by 10%  SDS-PAG E and W estern blotting w ith the anti-PM /Scl-75 rabbit serum. 
The positions of molecular mass markers are indicated in kDa at the right and the positions of the relevant po lypeptides at the left. Filled arrowheads 
indicate full-length proteins, open arrowheads indicate cleavage products and the asterisk indicates cross-reactivity of the anti-PM /Scl-75 serum.
Identification of the caspase cleavage site in PM/Scl-75
The association of the 45 kDa PM /Scl-75 fragm ent w ith the 
exosome (see above) suggested that this fragm ent represents 
the N-terminal part of the protein, because this region contains 
the RNase PH domain, which is involved in the association 
w ith the exosome complex [14]. Im m unoprecipitations per­
form ed w ith caspase-1-cleaved in  vitro-translated PM /Scl-75 
carrying a VSV-G  tag at either the N or C  term inus did indeed 
show  that the 45 kDa fragm ent could be precip itated only 
when the VSV tag was attached to the N term inus of the pro­
tein (data not shown). These data indicate that the major cas- 
pase cleavage site in P M /S cl-75 is located in the C-terminal 
domain of the protein.
To determ ine the exact position of the cleavage site in PM /Scl- 
75, substitution mutants were generated in which the aspartic 
acid residues marked in Figure 6a were replaced by alanine 
residues. Aspartic acid residues were chosen because each 
of the caspases requires this amino acid at the cleavage site, 
and thus replacement by alanine is expected to interfere with 
cleavage. A fter incubation w ith the recombinant caspase-3 or 
caspase-8, the specific  cleavage product was no longer 
observed w ith the PM /Scl-75 protein containing the substitu­
tion at position 369  (D369A) (Figure 6b, lanes 9 and 14), 
whereas the other m utations did not influence the cleavage of 
PM /Scl-75 by these caspases. In addition, when this mutant 
was incubated w ith caspase-1 the cleavage of PM /Scl-75 was
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F igure  5
Cleavage of PM /Scl-75 by recombinant caspases. (a ) 35S-labeled PM /S cl-75 translated in  vitro was incubated w ith 200 nM purified murine recom­
binant caspase-1, caspase-2, caspase-3, caspase-7, caspase-8 or caspase-11 for 1.5 hours at 37°C . The resulting reaction products were analyzed 
by 10%  SDS-PAGE, follow ed by autoradiography. In the first lane the mock-incubated protein was loaded. The filled arrowhead marks the full-length 
proteins and the open arrowhead the cleavage products. Note that in this experiment the pC I-neo-VSV-PM /Scl-75c-a cD N A was used for in vitro 
transcription and translation o f PM /Scl-75. The positions o f molecular mass markers are indicated in kDa at the right and the positions o f the relevant 
po lypeptides at the left. (b ) As a control for caspase activity the recombinant caspases were incubated w ith 5 0  |iM  fluorogenic substrate in 200 |il 
o f CFS buffer. The release of fluorescent 7-amino-4-methylcoumarin w as monitored for 1 hour at 37 °C  at 2-minute intervals in a fluorimeter. Data are 
expressed as the increase in fluorescence (Delta F) as a function o f time.
Page 6 o f 9
(page num ber no t fo r c ita tion  purposes)
A va ilab le  o n lin e  http ://arthritis-research.com /conten t/9/1 /R 1 2
Figure  6
Mapping of the caspase cleavage site in PM /Scl-75. (a ) Am ino acid sequence of PM /S cl-75 (a  variant). The RNase pleckstrin homology (PH) 
domain, the nuclear localization signal, the N termini o f both published sequences, PM /Scl-75a [13] and P M /S cl-75c [14], and the position (aster­
isk) where the ß splice variant contains a 17-amino-acid insertion are indicated. Note that the numbering of the amino acid positions corresponds to 
that of P M /S cl-75c-a. All aspartic acid residues that were replaced by alanines are highlighted in black. The mutants that were used in the experi­
ment shown in (b) are marked by arrows (D349A, D 363A  and D 374A) and the identified cleavage site by arrowheads (D369A). (b ) Cleavage of PM/ 
S cl-75 mutants by recombinant caspases. In vitro translated 35S-labeled P M /S c l-75c-a  and mutants o f the protein in w hich the aspartic acid resi­
dues at positions 347  (D347A), 36 3  (D363A), 368  (D 369A) or 374  (D374A) were changed into alanine residues were incubated w ith purified 
murine recombinant caspase-3 or caspase-8 for 1.5 hours at 37°C . The resulting reaction products were analyzed by SDS-PAG E followed by auto­
radiography. In lanes 1 to  5 the proteins incubated in parallel in the absence of caspases were loaded (control). The positions of molecular mass 
markers are indicated in kDa at the right, and the positions o f relevant po lypeptides are shown at the left. Filled arrowheads indicate full-length PM/ 
S c l-75c-a  and open arrowheads indicate the PM /S cl-75 cleavage product. Note that in this experiment the pC R 4-TO P O -P M /S cl-75c-a  cD N A [14] 
w as used for the transcription and translation o f PM /Scl-75 in  vitro. As a result o f translation initiation at an internal start codon in the reticulocyte 
lysate, a relatively high level o f a second polypeptide w as produced, w hich was shown to  represent a po lypeptide initiated at M et85, thus corre­
sponding to  P M /Scl-75a-a. W T, w ild type.
abolished (data not shown). Taken together, these data sug­
gest that the IILD369-lG  sequence represents the caspase 
cleavage site in the P M /S cl-75 protein during apoptosis.
Discussion
Although many different autoantibodies have been identified in 
a variety of autoimmune diseases, the mechanism that leads to
the production of most of these autoreactive antibodies is still 
unknown. During the past decade a substantial number of 
autoantigens have been shown to be m odified during apop to ­
sis and/or necrosis. This has led to the hypothesis that intrac­
ellular, m odified autoantigens are exposed to the immune 
system because of massive cell death and/or inefficient 
removal of dying cells, which could elicit a primary immune
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response targeting the modification on the autoantigen. In a 
secondary response, other parts of the autoantigenic molecule 
or its interacting partners m ight also be targeted by the 
immune system as a result of epitope spreading [1]. Patients 
w ith the PM /Scl overlap syndrome often develop antibodies 
against several com ponents of the human PM /Scl or exosome 
complex, especially against PM /Scl-100, P M /Scl-75 and 
hRrp4p [19]. Here we show  fo r the first time that one of the 
exosome subunits, PM /Scl-75, is specifica lly m odified during 
apoptosis. The generation of a PM /Scl-75 fragm ent in apop­
to tic  lysates of caspase-8-deficient Jurkat cells, the results 
from the caspase inhibitor studies in anti-Fas-treated cells, and 
the cleavage of PM /Scl-75 by different caspases in vitro 
resulting in a sim ilar cleavage pattern all suggest that several 
caspases are im plicated in the proteolytic cleavage of PM /Scl- 
75. However, we cannot exclude the possib ility that cleavage 
of PM /Scl-75 is not performed directly by caspases and is 
instead an indirect effect of the activation of other proteases 
during apoptosis. The cleavage of PM /Scl-75 occurs in the C- 
terminal part of the protein at the unconventional caspase 
cleavage site IILD369-lG . However, cleavage of other autoanti­
gens such as DNA topoisom erase I and Sm-F have also been 
reported to be cleaved by caspases at unconventional sites 
[16 ,20,21].
Consistent w ith the observation that the C-terminal part of the 
protein is cleaved during apoptosis, leaving the RNase PH 
domain intact, is our find ing that a subset of cleaved PM /Scl- 
75 m olecules remains associated w ith the core of the exo- 
some complex (Figure 3). A  very similar situation has been 
described for the Sm-F protein, which is cleaved apoptotically 
while remaining associated w ith the heptam eric ring of the Sm 
complex [16]. On the basis of interactions between exosome 
com ponents and structural sim ilarity w ith the bacterial protein 
polynucleotide phosphorylase, a model was generated fo r the 
structure of the human exosome. In this model the six proteins 
containing an RNase PH domain form the core of the exo­
some, which adopts a hexameric ring structure [22]. This 
model is strongly supported by the crystal structures of the 
archaeal, yeast and human exosome [23-26]. Interestingly, the 
crystal structure of the human exosome shows that the C -ter­
minal extension of PM /Scl-75 interacts w ith hRrp46 and 
wraps around both hRrp46 and O IP2 (hRrp43) on the outer 
surface of the ring, dem onstrating that the identified cleavage 
site of PM /Scl-75, which is located in the m iddle of this exten­
sion, is accessib le to caspases. The observation that PM /Scl- 
75 is cleaved during apoptosis m ight also have implications 
fo r the activity and function of the exosome complex.
Recently, it has been reported that the activity of the human 
exosome is restricted to the hRrp41 p -P M /S c l-7 5  het­
erodimer. As a consequence, cleavage of P M /S cl-75 may 
influence the catalytic activity of the complex [26]. Moreover, it 
has been shown that PM /Scl-75 contains a nuclear localiza­
tion signal, which has a role in the nucleolar targeting of PM /
S c l-75 [14]. The cleavage of PM /Scl-75 in apop to tic  cells 
removes the nuclear localization signal from the protein, which 
may change the subcellular distribution of the protein and the 
associated complex, as has been reported for the La autoanti­
gen [27]. It is therefore tem pting to speculate that cleavage of 
P M /S cl-75 leads to an increased exosome concentration in 
the cytoplasm and/or in the nucleoplasm, which may be 
required fo r an enhanced degradation rate of a variety of RNA 
m olecules in these com partm ents during apoptosis. S im ulta­
neously, cleavage of PM /S cl-75 would result in the release of 
the exosome from the nucleolus, leading to a loss of exosome 
function in this cellular compartment.
As described above, recent studies have led to the hypothesis 
that cell-death-induced m odifications can generate neo­
epitopes that trigger an autoimmune response. If the immune 
system is exposed to elevated and persistent levels of apop- 
totically m odified PM /Scl-75, this could contribute to breaking 
the immunological tolerance to the exosome complex, leading 
to the production of autoantibodies against com ponents of 
this complex. It would therefore be interesting to investigate 
whether the B-cell repertoires of PM /Scl patients in the early 
phase of the disease contain antibodies that are specifically 
reactive w ith the apop to tic  PM /Scl-75 protein fragment. Such 
autoantibodies that preferentially recognize apoptotically m od­
ified isoforms of the autoantigen have been shown to exist for 
the U1-70K  protein [28,29].
Conclusion
This study shows that the autoantigenic exosome com ponent 
P M /S cl-75 is specifica lly cleaved during apoptosis. A  45 kDa 
fragm ent of P M /S cl-75 is generated in apop to tic  Jurkat cells. 
This fragment, which corresponds to the N-terminal part of 
PM /Scl-75, is associated at least in part w ith the exosome 
complex. Cleavage assays in vitro w ith different recombinant 
caspases suggest that several caspases m ight be responsible 
for the proteolytic cleavage of PM /Scl-75, although caspase-
1 seems to be the most effective. The caspase cleavage site 
was mapped in the C-term inal part of the protein at A sp369 
(IILD369lG ) .
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